ASCO 2022 Conference Coverage
ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From the GRIFFIN Trial: Dara + Len, Bortezomib, and Dex in Transplant-Eligible NDMM
By
ASCO 2022 Conference Coverage
FEATURING
Cesar Rodriguez
By
ASCO 2022 Conference Coverage
FEATURING
Cesar Rodriguez
Login to view comments.
Click here to Login
